1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pharmarise Holdings Corp.

Pharmarise Holdings Corp.

TTSE:2796
508.00
JPY
+3.00
(+0.59%)
5.82BMarket Cap
Dec 17Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
4,820.35
4,388.02
5,386.58
5,863.21
6,036.25
5,655.81
5,397.82
5,622.95
5,530.61
5,534.76
5,175.4
5,609.47
6,139.79
- -
Basic EPS, GAAP
46.55
25.31
42.42
0.78
-3.1
2.51
61.03
45.78
47.9
35.42
-33.35
-32.42
10.07
- -
Free Cash Flow per Basic Share
53.1
307.89
-92.72
169.09
102.33
47.78
117.94
149.7
26.47
210.41
199.07
53.79
225.85
- -
Dividend per Share
13.24
13.99
15.88
13.84
13.94
13.67
13.65
13.86
14.04
13.94
12.07
19.79
13.96
- -
Book Value per Share
631.19
626.59
613.12
602.05
601.28
591.04
635.55
669.09
706.43
730.04
654.62
604.44
594.65
- -
Tangible Book Value per Share
-202.3
-128.07
-99.49
-80.43
-22.79
30.95
66.84
189.08
318.52
385.34
83.87
-35.12
-66.25
- -
Basic Weighted Avg Shares
8
9
9
9
9
9
9
9
9
9
11
11
11
11
Sales/Revenue/Turnover
38,221
39,506
48,511
52,949
54,562
51,728
51,030
52,324
51,608
52,030
54,466
63,508
69,512
- -
Operating Margin (%)
4.11
2.89
1.68
0.84
2.16
1.24
2.03
2.38
2.95
2.77
1.68
0.46
1.41
- -
Depreciation Expense
1,082
1,158
1,198
1,293
1,326
1,223
1,228
1,344
1,308
1,224
1,170
1,493
1,605
- -
Net Income, GAAP
369
228
382
7
-28
23
577
426
447
333
-351
-367
114
- -
Effective Tax Rate (%)
67.37
75.78
63.96
25,100
150.24
102.25
29.06
65.06
65.28
66.92
340.56
4,887.5
84.53
- -
Profit Margin (%)
0.97
0.58
0.79
0.01
-0.05
0.04
1.13
0.81
0.87
0.64
-0.64
-0.58
0.16
- -
Working Capital
-1,555
-2,367
-1,665
-1,440
-1,827
254
640
1,154
2,401
1,537
3,049
1,251
-846
- -
LT Debt
8,433
7,157
7,832
7,924
6,947
8,195
8,133
7,878
7,422
5,461
9,918
11,482
10,227
- -
Total Equity
5,629
5,811
6,237
5,900
5,622
5,614
5,942
6,331
6,698
6,986
7,440
6,916
6,857
- -
Return on Invested Capital (%)
2.94
1.62
1.72
-634.26
-3.52
-0.09
4.26
2.48
3.05
2.84
-11.93
-66.87
0.69
- -
Return on Capital (%)
2.51
1.61
2.69
-182.97
0.59
0.33
3.69
2.68
2.73
2.06
-2.86
-42.89
0.76
- -
Return on Common Equity (%)
7.56
4.11
6.84
0.13
-0.51
0.42
10.15
7.03
6.97
4.94
-4.93
-5.16
1.66
- -

Capital Structure

JPY

•

in mil. unless spec.
Nov'26
May'26
Aug'27
ST Debt
2,502
4,925
- -
LT Borrowings
9,869
9,810
- -
LT Finance Leases
- -
417
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
5,866
5,820
5,797

Working Capital

JPY

•

in mil. unless spec.
Nov'26
May'26
Aug'27
Total Current Assets
11,560
13,164
- -
Cash, Cash Equivalents & STI
2,555
6,016
- -
Accounts Receivable, Net
738
1,120
- -
Inventories
4,678
2,812
- -
Total Current Liabilities
11,284
14,010
- -
Payables & Accruals
- -
- -
- -
ST Debt
2,502
4,925
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.08%
1.74%
-0.85%
Free Cash Flow
67.84%
174.68%
319.87%
Net Income, GAAP
124.97%
-70.5%
-131.06%
Sales/Revenue/Turnover
3.84%
6.04%
9.45%
Total Cash Common Dividend
- -
- -
-29.46%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
63,508
2026
- -
- -
- -
- -
69,512
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-32.42
2026
- -
- -
- -
- -
10.07
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
19.79
2026
- -
- -
- -
- -
13.96
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Masayuki Akiyama
Full Time Employees
2,031
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Sumitomo Nakano Sakue Building Tokyo TY Japan 164-0011
IPO Date
Feb 1, 2007
Website
pharmarise.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pharmarise Holdings Corporation Pharmarise Holdings Corporation (2796.T) serves as a Japan-based holding company primarily engaged in the management and operation of dispensing pharmacies, drug stores, and convenience stores across Japan. The company offers core services including prescription dispensing based on medical institution prescriptions; operation of drug and convenience stores with sales of cosmetics and over-the-counter products; storage and management of patient medical examination records on behalf of medical institutions; operation of medical malls; provision of system integration services and medical IT solutions to pharmaceutical companies; and temporary help and employment placement services. Established in June 1984 and headquartered at 1-38-1 Chuo, Nakano-ku, Tokyo, Japan, Pharmarise Holdings operates approximately 399 stores as of June 2024, with 1,869 consolidated employees as of May 2022, primarily targeting community healthcare needs in an aging Japanese population through its core dispensing pharmacy segment, which accounts for over 80% of net sales. Recent major developments include the acquisition of the GOOD AID Group, adding 38 stores, completed in January 2024; the acquisition of the Nagisa Group, incorporating 54 stores, finalized in December 2024; and a capital and business alliance with Suzuken Corporation, where Suzuken increased its stake to 20% by January 2024 to enhance collaboration in pharmacy operations and digital transformation initiatives. These expansions, alongside investments in family pharmacist guidance fees, community support system premiums, and dispensing at elderly care facilities, position the company for industry consolidation amid dispensing fee revisions and national health insurance adjustments, while its medium-term management plan targets sustainable growth through enhanced operational efficiency and store network expansion.